EP
SPRY icon

Eversept Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Eversept Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.02M Buy
377,007
+240,772
+177% +$2.07M 0.16% 78
2026
Q1 		$1.09M Sell
136,235
-115,358
-46% -$1.11M 0.06% 105
2025
Q4 		$2.93M Sell
251,593
-724,918
-74% -$7.05M 0.15% 80
2025
Q3 		$9.81M Buy
+976,511
New +$14M 0.68% 35
2023
Q3 		– Sell
-48,788
Closed -$327K – 76
2023
Q2 		$327K Buy
+48,788
New +$326K 0.03% 69

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Eversept Partners's SPRY Position: Q2 2026 in Review

Eversept Partners increased its ARS Pharmaceuticals (SPRY) stake by 177% in Q2 2026, buying an estimated $2.07M and bringing the position to 377,007 shares worth $3.02M. The position accounts for 0.16% of the portfolio, ranked #78.

Eversept Partners first reported a position in SPRY in Q2 2023 and has held it in 5 quarters since. The position peaked at $9.81M in Q3 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Eversept Partners held 377,007 shares of ARS Pharmaceuticals worth $3.02M as of Q2 2026.
  • Eversept Partners bought 240,772 ARS Pharmaceuticals shares in Q2 2026, an estimated $2.07M.
  • ARS Pharmaceuticals made up 0.16% of Eversept Partners's portfolio in Q2 2026, its #78 holding.
  • Eversept Partners first reported a position in ARS Pharmaceuticals in Q2 2023 and has held it in 5 quarters since.
  • Eversept Partners's ARS Pharmaceuticals position peaked at $9.81M in Q3 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.